This is a group of rare genetic disorders. It affects how fats (lipids) build up in the body, specifically in organs like the liver and spleen, and in the brain. This buildup causes serious health problems.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
Niemann-Pick diseases are rare inherited conditions in which fats build up inside the body's cells instead of being broken down or moved where they belong. Over time that buildup damages organs, most often the liver, spleen and lungs, and in some forms the brain. The name covers two different diseases that share a history rather than a cause. Acid sphingomyelinase deficiency (ASMD), which includes the forms once called types A and B, happens when the body lacks an enzyme that breaks down a fat called sphingomyelin. Type A begins in infancy and affects both the body and the brain severely. Type B can appear anywhere from childhood to adulthood and mainly affects the organs, typically with an enlarged liver and spleen, lung problems and low platelet counts, usually without brain involvement. Some people fall between the two. Niemann-Pick disease type C (NPC) is a separate condition in which cells cannot move cholesterol and other fats to where they are needed. It mainly affects the brain and nervous system, causing problems with balance, coordination, swallowing, speech, thinking and behavior that worsen over time. A characteristic early sign is difficulty moving the eyes up and down. NPC can start at almost any age, from before birth to adulthood.
All forms of Niemann-Pick disease are genetic. ASMD is caused by changes in the SMPD1 gene, and type C by changes in the NPC1 gene (about 95 percent of cases) or the NPC2 gene. Nothing a person or parent did causes the disease, and there are no known lifestyle triggers. The conditions are inherited in an autosomal recessive pattern, meaning a person must inherit a changed copy of the gene from both parents. Each parent usually carries one changed copy without having symptoms. When both parents are carriers, each pregnancy has a one in four chance of the child being affected. These diseases occur worldwide. Type A is more common among people of Ashkenazi Jewish descent, and type C occurs more often in a French-Acadian community in Nova Scotia, but anyone can be affected.
Because the early signs, such as an enlarged spleen, low platelets, clumsiness or learning difficulties, are shared with many other conditions, diagnosis is often delayed. In adults with type C, a delay of five years or more is common. For ASMD, the first step is a blood test that measures acid sphingomyelinase enzyme activity; very low activity confirms the diagnosis. Genetic testing of the SMPD1 gene follows, which can help predict how the disease is likely to behave. Doctors often test for Gaucher disease at the same time, since it can look similar. For type C, specialized blood tests that detect abnormal fat byproducts are usually the first screen, and genetic testing for changes in both copies of NPC1 or NPC2 confirms the diagnosis. Eye movement examination, imaging and hearing, swallowing and thinking assessments help show how far the disease has progressed. Once a diagnosis is made, genetic counseling can explain what it means for siblings and future pregnancies.
There is no cure for either disease, but treatment can now slow or reduce some of the damage, and supportive care addresses each affected organ. Care works best through a center experienced in these rare conditions. For ASMD, olipudase alfa (Xenpozyme) is an enzyme replacement therapy: it supplies the missing enzyme so cells can break down stored sphingomyelin. It is given as an intravenous infusion every two weeks, starting at a low dose that is raised gradually. In a trial with up to five years of treatment, adults saw their spleens shrink by more than half and their lung function improve. It treats the body's organs, not the brain, so it does not help the neurological decline of type A. Infusions are given with medical monitoring because serious allergic reactions can occur. For type C, three medicines aim to slow neurological decline. Miglustat, an oral medicine that reduces production of certain fats, has been used for years and is recommended by expert guidelines, although its US approval is for Gaucher disease. Arimoclomol (Miplyffa), taken together with miglustat, and levacetylleucine (Aqneursa) are approved in the US for the neurological symptoms of type C. In trials they slowed or modestly improved measures of movement and daily function; they do not reverse damage already done. Diarrhea and weight loss are common with miglustat. Several of these medicines may harm a developing baby, so pregnancy planning is part of the treatment discussion. Supportive care matters in every form: physical, speech and occupational therapy; treatment of seizures, sleep problems, mood or psychiatric symptoms; nutrition support; and monitoring of the liver, lungs, cholesterol levels and blood counts.
The outlook depends heavily on the form and, in type C, on the age when neurological symptoms begin. Type A usually leads to death in early childhood, often from lung infections. People with type B often live into adulthood, sometimes with a normal lifespan, though lung disease, liver scarring and bleeding from low platelets can shorten life. An unhealthy cholesterol pattern often appears early in type B and can raise the risk of heart disease over time. Type C is progressive. The earlier neurological symptoms start, the faster the course tends to be; people whose symptoms begin in adolescence or adulthood may live for decades. Over time, walking, speech and swallowing usually become harder, and thinking and behavior can change. Many children with later-onset type C reach adulthood with complex needs, so planning the move from pediatric to adult care early helps. Regular follow-up tracks how each organ is doing and whether treatment is working. In type C, swallowing is checked regularly, and a feeding tube placed through the abdominal wall (a gastrostomy) is considered when eating by mouth becomes unsafe. Families often benefit from social work support, respite care, patient organizations and, as needs grow, palliative care focused on comfort and quality of life.
Ask for an evaluation if a child or adult has an unexplained enlarged liver or spleen, persistently low platelets, repeated lung infections, or a combination of clumsiness, learning or behavior changes and trouble looking up or down. A family history of Niemann-Pick disease is a reason to discuss carrier or diagnostic testing. For someone already diagnosed, contact the care team when there is new coughing or choking with meals, weight loss, more frequent falls, new seizures, worsening mood or behavior, or easy bruising and nosebleeds. Seek care the same day for a fever or breathing difficulty in a person with significant lung involvement, since chest infections can become serious quickly.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Niemann-Pick Diseases is like, what's helped you, or ask the community a question.